Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say

Executive Summary

Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.

Advertisement

Related Content

Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
ASCO Value Framework Could Inform Clinical Pathways, Payers Say
UnitedHealth Cancer Care Pilot Reduced Overall Costs Despite Higher Drug Spending
WellPoint Cancer Drug Pathways Program Aims To Save 4% In Annual Costs
Cost-Consciousness Raising: Adding Value To Cancer Drug Development
Cost-Consciousness Raising: Adding Value To Cancer Drug Development
UnitedHealth Pursuing Payer/Pharma Collaboration To Evaluate Novel Cancer Treatments
Honing In On Value At Citicorp Healthcare Conference
What New Cancer Pathway Programs Mean For The Drug Industry

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel